Genome-wide methylation profiling has revealed a novel differentially methylated biomarker, metallophosphoesterase domain containing 2 (MPPED2), demonstrating methylation alterations across the progression from normal mucosa to hyperplastic polyps, adenomas, and carcinomas. This evidence concerns the gene MPPED2 and carcinoma.